387 related articles for article (PubMed ID: 15020034)
1. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
Mayo MS; Gajewski BJ
Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
3. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
[TBL] [Abstract][Full Text] [Related]
4. Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors.
Gajewski BJ; Mayo MS
Stat Med; 2006 Aug; 25(15):2554-66. PubMed ID: 16345057
[TBL] [Abstract][Full Text] [Related]
5. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
Zohar S; Teramukai S; Zhou Y
Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
[TBL] [Abstract][Full Text] [Related]
6. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
Daimon T
Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
[TBL] [Abstract][Full Text] [Related]
7. Robust Bayesian sample size determination in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2008 Jun; 27(13):2290-306. PubMed ID: 18205170
[TBL] [Abstract][Full Text] [Related]
8. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
Gordon Lan KK; Wittes JT
Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
[TBL] [Abstract][Full Text] [Related]
9. Practical Bayesian guidelines for phase IIB clinical trials.
Thall PF; Simon R
Biometrics; 1994 Jun; 50(2):337-49. PubMed ID: 7980801
[TBL] [Abstract][Full Text] [Related]
10. Sample size determination for phase II clinical trials based on Bayesian decision theory.
Stallard N
Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
[TBL] [Abstract][Full Text] [Related]
11. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
Brutti P; Gubbiotti S; Sambucini V
Stat Med; 2011 Jun; 30(14):1648-64. PubMed ID: 21520453
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
Sambucini V
Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
[TBL] [Abstract][Full Text] [Related]
13. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
14. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
15. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
16. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
17. Optimal sample size determinations from an industry perspective based on the expected value of information.
Willan AR
Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
[TBL] [Abstract][Full Text] [Related]
18. Sample-size calculations for trials that inform individual treatment decisions: a 'true-choice' approach.
Girling AJ; Lilford RJ; Braunholtz DA; Gillett WR
Clin Trials; 2007; 4(1):15-24. PubMed ID: 17327242
[TBL] [Abstract][Full Text] [Related]
19. Sample size reestimation by Bayesian prediction.
Wang MD
Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian design and analysis for dose-response using informative prior information.
Smith MK; Marshall S
J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
